Comparing Pazopanib vs Sunitinib
| Pazopanib | Sunitinib |
|
|---|
| Pazopanib | Sunitinib |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. Pazopanib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Gastrointestinal Stromal Tumor, Renal Cell Carcinoma, Pancreatic Cancer. Sunitinib may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Pazopanib | More about Sunitinib | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Pazopanib has an average rating of 8.0 out of 10 from a total of 92 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 9% reported a negative effect. |
Sunitinib has an average rating of 7.3 out of 10 from a total of 35 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Pazopanib side effects |
View all Sunitinib side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
Lower cost generic |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Pazopanib prices |
View all Sunitinib prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Votrient | Sutent | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
30.9 hours |
60 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 710 drugs are known to interact with Pazopanib:
|
A total of 495 drugs are known to interact with Sunitinib:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
October 19, 2009 |
January 26, 2006 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.